or Try an Advanced Search...

    Technical Analysis for OLMA - Olema Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    D 10.52 3.44% 0.35
    OLMA closed up 0.1 percent on Tuesday, April 30, 2024, on approximately normal volume.
    Earnings due: May 7
    *** please verify all earnings dates ***
    5 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Up
    Historical OLMA trend table...
    Date Alert Name Type % Chg
    Lower Bollinger Band Walk Weakness 3.44%
    Multiple of Ten Bullish Other 3.44%
    Up 3 Days in a Row Strength 3.44%
    Gapped Down Weakness 3.44%
    Lower Bollinger Band Touch Weakness 3.44%
    MACD Bullish Signal Line Cross Bullish 3.54%
    Multiple of Ten Bullish Other 3.54%
    Lower Bollinger Band Walk Weakness 5.73%
    Multiple of Ten Bearish Other 5.73%
    BB Squeeze Ended Range Expansion 5.73%
    Older End-of-Day Signals for OLMA ...

       Recent Intraday Alerts

    Alert Time
    Rose Above 20 DMA 6 minutes ago
    10 DMA Support about 5 hours ago
    Rose Above Previous Day's High about 5 hours ago
    20 DMA Resistance about 5 hours ago
    Up 3% about 5 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    OLMA Chart by TradingView
    Basic chart:

    Profile

    Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is an orally available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer. Olema is headquartered in San Francisco.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Clinical Medicine Breast Cancer Treatment Of Breast Cancer Epidermal Growth Factor Receptor Hormones Targeted Therapy Her2 Her2/Neu Estrogen Antiestrogens Estrogen Receptor Selective Estrogen Receptor Degraders Fulvestrant

    Is OLMA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 1 Olema Oncology to Participate in Upcoming Investor Conferences in May
    Apr 8 Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
    Apr 5 Goldman Sachs Predicts Over 120% Rally for These 2 ‘Strong Buy’ Stocks
    Mar 28 Palazestrant's Journey: Olema Pharmaceuticals' Long Oncology Path
    Mar 11 Olema Pharmaceuticals GAAP EPS of -$0.49
    Mar 11 Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
    Mar 6 Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors
    Mar 4 Calculating The Intrinsic Value Of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)
    Feb 2 Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    Jan 31 Olema Pharmaceuticals files to sell 13.21M common shares for holders
    See more OLMA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 17.7911
    52 Week Low 5.05
    Average Volume 840,256
    200-Day Moving Average 12.15
    50-Day Moving Average 11.74
    20-Day Moving Average 10.54
    10-Day Moving Average 10.07
    Average True Range 0.71
    RSI (14) 41.52
    ADX 35.37
    +DI 10.29
    -DI 27.91
    Chandelier Exit (Long, 3 ATRs) 9.61
    Chandelier Exit (Short, 3 ATRs) 11.32
    Upper Bollinger Bands 11.65
    Lower Bollinger Band 9.43
    Percent B (%b) 0.33
    BandWidth 21.00
    MACD Line -0.48
    MACD Signal Line -0.52
    MACD Histogram 0.0365
    Fundamentals Value
    Market Cap 560.34 Million
    Num Shares 55.1 Million
    EPS -2.31
    Price-to-Earnings (P/E) Ratio -4.40
    Price-to-Sales 0.00
    Price-to-Book 3.05
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 11.84
    Resistance 3 (R3) 11.71 11.01 11.56
    Resistance 2 (R2) 11.01 10.59 11.08 11.47
    Resistance 1 (R1) 10.59 10.32 10.80 10.73 11.38
    Pivot Point 9.90 9.90 10.00 9.97 9.90
    Support 1 (S1) 9.48 9.47 9.69 9.61 8.96
    Support 2 (S2) 8.78 9.21 8.85 8.87
    Support 3 (S3) 8.36 8.78 8.78
    Support 4 (S4) 8.50